Ann Arbor, MI, United States of America

Haruki Hasegawa


Average Co-Inventor Count = 10.2

ph-index = 1


Location History:

  • Kyoto, JP (2004)
  • Ann Arbor, MI (US) (2006)

Company Filing History:


Years Active: 2004-2006

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Haruki Hasegawa: Innovator in Pharmaceutical Chemistry

Introduction

Haruki Hasegawa is a notable inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for treating inflammatory diseases. With a total of 3 patents to his name, Hasegawa's work has the potential to impact medical treatments significantly.

Latest Patents

Hasegawa's latest patents include innovative compounds that serve as integrin receptor antagonists. The first patent focuses on beta-amino acid derivatives, detailing the compounds' general formula, processes for their preparation, and their use in pharmaceutical compositions aimed at treating inflammatory diseases. The second patent involves succinic acid derivatives, which also outlines similar processes and applications in the pharmaceutical field.

Career Highlights

Throughout his career, Haruki Hasegawa has worked with prominent companies such as Bayer Aktiengesellschaft and Bayer Healthcare Aktiengesellschaft. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Hasegawa has collaborated with notable colleagues, including Markus Albers and Thomas Lehmann. These partnerships have likely contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Haruki Hasegawa's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the field. His work continues to pave the way for advancements in treatments for inflammatory diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…